How long does stem cell therapy for ALS (Motor Neurone Disease) last?
There is insufficient controlled evidence to promise a functional plateau, survival benefit, response window or repeat-treatment interval. ALS progression varies between people, so trials need prespecified comparators and longitudinal ALSFRS-R, respiratory and survival outcomes. Providers should not attribute temporary stability to an unapproved product without controlled evidence.
How stem cells are studied for ALS (Motor Neurone Disease)
Amyotrophic lateral sclerosis (ALS or motor neurone disease) is a neurodegenerative condition characterised by progressive loss of motor neurons in the spinal cord, brainstem and motor cortex. Multiple mechanisms are under investigation, including excitotoxicity, mitochondrial dysfunction, protein misfolding and neuroinflammation. Neural progenitor and mesenchymal stromal cell approaches are being studied for proposed neuroprotective or supportive effects, but these mechanisms have not established slowed progression or restored motor function in people. The registry table on this page lists relevant studies and their current recruitment status.
Am I a candidate? → · ALS (Motor Neurone Disease): full overview → · ALS (Motor Neurone Disease) cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.
Sources & further reading
More on this condition
- ALS (Motor Neurone Disease): cell-therapy evidence and registered trials
- How much does stem cell therapy for ALS (Motor Neurone Disease) cost? (2026)
- ALS (Motor Neurone Disease) stem cell therapy — your questions answered (2026)
- ALS (Motor Neurone Disease): cell-therapy evidence by therapy class
- MSC vs HSCT for ALS (Motor Neurone Disease): what the registries show